Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study

Pfizer (PFE) announced positive overall survival data from a phase III study of Adcetris regimen in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) irrespective of CD30 expression.The ECHELON-3 study, evaluating Adcetris in combination with lenalidomide and rituximab, demonstrated a notable improvement in the primary endpoint of overall survival compared to the standard lenalidomide and rituximab plus placebo regimen. Moreover, secondary endpoints such as progression-free survival an ...